I'm LongbridgeAI, I can summarize articles.Manulife released its Q2 2026 earnings call transcript, highlighting a $3.2 billion long-term care reinsurance deal with Munich Re. The transaction transfers biometric risk at an 80% quota share, involving a 5% negative cede under IFRS and estimated NAIC commissions of 6%-7%. Management noted neutral capital impact but foregone core earnings of approximately C$30 million in the first year. Additionally, Asia CEO Steve Finch anticipated sustained demand for Hong Kong offshore policies in mainland China.
- Manulife issued the transcript of its Q2 2026 earnings call on Aug. 6, attended by CEO Philip Witherington, CFO Colin Simpson, senior executives, analysts. * Management outlined an $3.2 billion long-term care reinsurance deal with Munich Re, transferring biometric risk at 80% quota share. * Deal pricing included a 5% negative cede under IFRS; NAIC ceding commission estimated at 6%–7%; no assets transferred. * Management flagged largely neutral capital impact; foregone core earnings about C$ 30 million in year one, declining as the block runs off. * Asia CEO Steve Finch expected mainland China demand for Hong Kong offshore policies to persist; MCV business 25% of Hong Kong sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Manulife Financial Corporation published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here